Sylvester Comprehensive Cancer Center is collaborating with Moffitt Cancer Center and the University of Florida Health Cancer Center to fund four grants that will bring cancer prevention and detection education to high-risk Florida communities.
The 2024 Florida Academic Cancer Center Alliance (FACCA) Annual Retreat was held April 1-2 in Orlando. See photos…
After crossing the Atlantic Ocean and meeting with a team at Mayo, John Cadwallader learned he was a candidate for chimeric antigen receptor-T cell therapy, or CAR-T. The personalized treatment collects a patient's T cells, which normally help fight off infections, and genetically engineers them to target cancer cells.
Courtney has always been a planner, even as a child. Growing up in Gainesville, she produced pretend weddings for her sister and neighborhood friends, ensuring every detail was perfect. In high school, she was elected junior class social committee president and expanded the number of dances their class held from just one to four.
Every day, patients buzz in and out of the clinic on the first floor of Moffitt Cancer Center’s Magnolia campus. They are picking up medications to ensure their T cell counts are high enough to continue receiving infusion and compatible with their ongoing cancer treatments. These patients are part of a special population. Many have already faced a battle for their lives against one disease. Then, they were diagnosed with cancer.
The 2023 Annual FACCA retreat will be held March 27-28.
Cancer is the second leading cause of death for Floridians, with heart disease being number one. Since 2001, the Florida Legislature has recognized the need to support vital research conducted in both academic and private institutions throughout the state. This symposium will serve as a gathering point to collaborate…
Sylvester Comprehensive Cancer Center, South Florida’s only NCI-Designated Cancer Center, is excited to sponsor our 3rd Biennial Miami Leukemia Symposium. This year’s meeting experience will include engaging talks from world-renowned scientists discussing the latest advances in Leukemia. We are excited to host this in-person event at the JW Marriott…
Chimeric antigen receptor T-cell therapy, or CAR T, has been a huge breakthrough for certain types of blood cancers. First approved in 2017, the therapy uses a patient’s own immune cells, which are removed and sent to a lab where they are genetically engineered, adding a receptor to help them better seek out cancer cells. Once infused back into the patient, the CAR T cells can easily find and attack the tumors.
